A detailed history of Alliancebernstein L.P. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Alliancebernstein L.P. holds 81,919 shares of PTGX stock, worth $3.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
81,919
Previous 95,169 13.92%
Holding current value
$3.22 Million
Previous $3.3 Million 11.65%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$33.72 - $47.33 $446,790 - $627,122
-13,250 Reduced 13.92%
81,919 $3.68 Million
Q2 2024

Aug 14, 2024

BUY
$24.66 - $34.8 $240,903 - $339,961
9,769 Added 11.44%
95,169 $3.3 Million
Q4 2023

Feb 14, 2024

SELL
$14.05 - $23.44 $26,301 - $43,879
-1,872 Reduced 2.15%
85,400 $1.96 Million
Q3 2023

Nov 14, 2023

BUY
$16.68 - $23.66 $117,960 - $167,323
7,072 Added 8.82%
87,272 $1.46 Million
Q2 2023

Aug 15, 2023

BUY
$18.02 - $29.36 $468,520 - $763,360
26,000 Added 47.97%
80,200 $2.22 Million
Q4 2022

Feb 14, 2023

BUY
$7.36 - $11.17 $104,512 - $158,614
14,200 Added 35.5%
54,200 $591,000
Q3 2022

Nov 15, 2022

SELL
$7.86 - $11.71 $47,160 - $70,260
-6,000 Reduced 13.04%
40,000 $337,000
Q2 2022

Aug 15, 2022

SELL
$7.06 - $25.52 $568,068 - $2.05 Million
-80,463 Reduced 63.63%
46,000 $364,000
Q1 2022

May 13, 2022

BUY
$23.34 - $36.08 $1.88 Million - $2.91 Million
80,563 Added 175.52%
126,463 $3 Million
Q2 2021

Jul 30, 2021

BUY
$25.57 - $44.88 $391,221 - $686,664
15,300 Added 50.0%
45,900 $2.06 Million
Q1 2021

May 06, 2021

BUY
$19.02 - $31.15 $49,452 - $80,990
2,600 Added 9.29%
30,600 $793,000
Q2 2020

Aug 13, 2020

BUY
$6.19 - $18.84 $73,661 - $224,196
11,900 Added 73.91%
28,000 $494,000
Q1 2020

May 14, 2020

BUY
$5.4 - $9.22 $18,900 - $32,270
3,500 Added 27.78%
16,100 $114,000
Q3 2019

Nov 14, 2019

BUY
$9.41 - $16.56 $118,566 - $208,655
12,600 New
12,600 $151,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.93B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.